AMPH vs HQY: fair value comparison
Amphastar Pharmaceuticals, Inc. and HealthEquity, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMPH currently sits closer to the top of our discount ranking. HQY carries the stronger quality grade.
| AMPH | HQY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $20.22 | $104.36 |
| 12-month range | $18.42–$30.81 | $77.93–$104.36 |
| Sector rank | #15 of 113 Healthcare | #20 of 113 Healthcare |
| Quality grade | C- | C |
| Momentum grade | A | A |
| Leverage | Moderate | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AMPH fair value analysis · HQY fair value analysis